Among management options for node-positive upper tract urothelial cancer (UTUC), induction chemotherapy added to radical nephroureterectomy (RNU) provides the best cancer control and survival outcomes ...

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

Our study provides insight into the treatment landscape and outcomes for metastatic urothelial carcinoma in Mexico and highlights the need for improved access to novel therapies. These findings can ...

Patients with muscle-invasive urothelial cancer face a high risk of relapse despite radical surgery and chemotherapy. The immune checkpoint inhibitor pembrolizumab may reduce this risk.

Ami Fadia, an analyst from Needham, maintained the Buy rating on Bicycle Therapeutics (BCYC – Research Report). The associated price target ...

Bladder cancers comprise heterogeneous cell populations, and numerous factors are likely to be involved in dictating recurrence, progression and patient survival. While several molecular markers ...

UroGen Pharma Ltd., a pioneering pharmaceutical company with a focus on innovative treatments for urothelial cancers, recently submitted an 8-K form to the Securities and Exchange Commission, ...

Duravelo-1 trial showed a 60% overall response rate for zelenectide pevedotin plus pembrolizumab in metastatic urothelial cancer. NECTIN4 gene amplification linked to higher response rates in ...